| CBDX Stock | | | USD 0.0001 0.00 0.00% |
Insider
A Grandsaert is President of Curative Biosciences
| Age | 80 |
| Phone | 949-287-3164 |
| Web | https://curativebio.com |
Curative Biosciences Management Efficiency
The company has return on total asset
(ROA) of
(38.439) % which means that it has lost $38.439 on every $100 spent on assets. This is way below average. Curative Biosciences' management efficiency ratios could be used to measure how well Curative Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.
Curative Biosciences currently holds 156.45
K in liabilities. Debt can assist Curative Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Curative Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Curative Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Curative to invest in growth at high rates of return. When we think about Curative Biosciences' use of debt, we should always consider it together with cash and equity.
Curative Biosciences, Inc. focuses on developing and commercializing therapeutics using hemp-derived Cannabidiol. Curative Biosciences, Inc. was founded in 2009 and is based in Miami, Florida. Curative Biosciences is traded on OTC Exchange in the United States. Curative Biosciences [CBDX] is a
Pink Sheet which is traded between brokers over the counter.
Management Performance
Curative Biosciences Leadership Team
Elected by the shareholders, the Curative Biosciences' board of directors comprises two types of representatives: Curative Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Curative. The board's role is to monitor Curative Biosciences' management team and ensure that shareholders' interests are well served. Curative Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Curative Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
Curative Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Curative Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Curative Pink Sheet Analysis
When running Curative Biosciences' price analysis, check to
measure Curative Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biosciences is operating at the current time. Most of Curative Biosciences' value examination focuses on studying past and present price action to
predict the probability of Curative Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biosciences' price. Additionally, you may evaluate how the addition of Curative Biosciences to your portfolios can decrease your overall portfolio volatility.